Cardiovascular Systems
Cardiovascular Systems, Inc., established in 1989, specializes in developing and marketing innovative medical technologies for treating peripheral and coronary artery diseases. The company's primary product line is its orbital atherectomy systems, which employ a diamond-coated crown to remove plaque from arteries above and below the knee. These catheter-based platforms are designed to tackle challenging disease states, including calcium buildup, which is particularly prevalent in peripheral artery disease (PAD) and coronary artery disease (CAD). Cardiovascular Systems generates most of its revenue through sales of these peripheral orbital atherectomy systems in the United States.
Top Stages
3 past transactions
CarePICS
Corporate Round in 2021
CarePICS is a software application development company focused on enhancing clinical outcomes in the healthcare industry. It has developed an online consultation platform specifically designed for patients suffering from peripheral artery disease. This platform enables podiatrists, skilled nursing facilities, home health agencies, and primary care physicians to capture essential patient information, including wound images and measurements. By facilitating remote consultations, CarePICS helps remove barriers to care, allowing patients to manage their health more effectively without the need for in-person clinic visits.
Leviticus Cardio
Venture Round in 2015
Leviticus Cardio Ltd is a medical technology company based in Petach Tikva, Israel, focused on developing innovative solutions for patients with congestive heart failure. Founded in 2008, the company specializes in a wireless coplanar energy transfer system designed to power implanted ventricular assist devices (VADs). Leviticus Cardio's flagship product, the Fully Implanted Ventricular Assist Device (FIVAD), eliminates the need for external power packs and drive lines, addressing the significant risk of infection associated with traditional VADs. This advanced system is designed to meet the daily power needs of patients, enabling them to receive long-term mechanical circulatory support while maintaining adequate blood flow. By simplifying the implantation process and enhancing the overall patient experience, Leviticus Cardio aims to improve outcomes for the substantial number of heart failure patients who rely on VADs.
Replidyne
Acquisition in 2008
Replidyne is a specialty pharmaceutical company dedicated to developing and commercializing innovative anti-infective products. The company focuses on addressing complex issues in skin care treatment through its bio-pharmaceutical offerings, which include oral community antibiotics and interventional treatment systems. Replidyne leverages its proprietary DNA replication technology and pursues in-licensing opportunities to enhance its development pipeline. This approach enables the company to provide a diverse range of products aimed at effectively treating skin wounds and related conditions, ultimately benefiting patients and medical providers alike.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.